View in EDS

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Saved in:
Bibliographic Details
Title: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Authors: Wu, Yi-Long1 syylwu@live.cn, Cheng, Ying2, Zhou, Xiangdong3, Lee, Ki Hyeong4, Nakagawa, Kazuhiko5, Niho, Seiji6, Tsuji, Fumito7, Linke, Rolf8, Rosell, Rafael9, Corral, Jesus10, Migliorino, Maria Rita11, Pluzanski, Adam12, Sbar, Eric I13, Wang, Tao14, White, Jane Liang14, Nadanaciva, Sashi14, Sandin, Rickard15, Mok, Tony S16
Source: Lancet Oncology. Nov2017, Vol. 18 Issue 11, p1454-1466. 13p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(17)30608-3